Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has issued an announcement.
Clarity Pharmaceuticals Ltd announced the quotation of 19,785 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code CU6. This move reflects the company’s ongoing efforts to enhance its market presence and provide value to its stakeholders by expanding its capital base.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$8.20 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment of serious diseases. The company is primarily engaged in providing innovative solutions in the field of nuclear medicine.
Average Trading Volume: 3,251,872
Technical Sentiment Signal: Buy
Current Market Cap: A$1.41B
For a thorough assessment of CU6 stock, go to TipRanks’ Stock Analysis page.